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Association of REL polymorphisms 
and outcome of patients with septic shock
Julie Toubiana1,2,3*†, Emilie Courtine1,2†, Frederic Tores4, Pierre Asfar5, Cédric Daubin6, Christophe Rousseau2, 
Fatah Ouaaz2, Nathalie Marin7, Alain Cariou1,7, Jean‑Daniel Chiche1,2,7 and Jean‑Paul Mira1,2,7
Abstract 
Background: cRel, a subunit of NF‑κB, is implicated in the inflammatory response observed in autoimmune disease. 
Hence, knocked‑out mice for cRel had a significantly higher mortality, providing new and important functions of cRel 
in the physiopathology of septic shock. Whether genetic variants in the human REL gene are associated with severity 
of septic shock is unknown.
Methods: We genotyped a population of 1040 ICU patients with septic shock and 855 ICU controls for two known 
polymorphisms of REL; REL rs842647 and REL rs13031237. Outcome of patients according to the presence of REL variant 
alleles was compared.
Results: The distribution of REL variant alleles was not significantly different between patients and controls. Among 
the septic shock group, REL rs13031237*T minor allele was not associated with worse outcome. In contrast, REL 
rs842647*G minor allele was significantly associated with more multi‑organ failure and early death [OR 1.4; 95 % CI 
(1.02–1.8)].
Conclusion: In a large ICU population, we report a significant clinical association between a variation in the human 
REL gene and severity and mortality of septic shock, suggesting for the first time a new insight into the role of cRel in 
response to infection in humans.
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Background
Despite continued efforts and significant advances in 
critical care medicine, septic shock remains a signifi-
cant health problem with a mortality rate around 35  % 
[1, 2]. Septic shock is defined as sepsis accompanied 
by cardiovascular failure that is often a part of multiple 
organ dysfunction syndrome (MODS) [3]. Thus, sep-
tic shock represents an extreme manifestation of the 
host inflammatory response to severe infection. Tran-
scription of inflammatory mediators such as cytokines, 
chemokines, adhesion molecules and reactive oxygen 
species is strongly activated by the transcriptional factor 
NF-κB and contributes to the development of MODS [4, 
5]. NF-κB is an ubiquitous family of inducible dimeric 
homodimer or heterodimer transcriptional factors com-
posed by five members: Rel (c-Rel), RelA (p65), RelB, 
NF-κB1 (p50/p105) and NF-κB2 (p52/p100) [6].
The role of RelA in severe infection is well established, 
as it is highly recruited to the promoter of pro-inflam-
matory genes in non-survivors of septic shock [7, 8]. The 
cRel subunit was the least studied member of the Rel 
family, but seems to have also a critical role in the antimi-
crobial host defense. Indeed, in vivo studies revealed that 
cRel is required for macrophage activation [9, 10], adap-
tive immunity [11] and the control of lymphocyte prolif-
eration [12, 13]. cRel is also a key regulator of numerous 
cytokines: IL-2, IL-3, IL-4, IL-6, IL-10, IL-13, IL-15, 
IL-21, IFN-γ, IFN-β, IFN-λ, MIP1-α and GM-CSF [9, 
14–19]. More recently, in a murine model of polymicro-
bial sepsis, Rel deficiency led to an increased mortality, 
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an enhanced systemic inflammatory response and a sus-
tained depletion of spleen lymphoid dendritic cells [9–12, 
20]. Furthermore, whole blood transcriptomics showed 
that cRel targets inflammatory and survival genes during 
sepsis [13, 20]. Moreover, genetic variants within the REL 
locus have been associated with inflammatory diseases or 
autoimmunity in Europeans [21]. Even if no study reports 
the importance of cRel in human sepsis, these elements 
highlight the potential importance of cRel for NF-κB tar-
geted-immunomodulation in severe infections.
Recently, the role of genetic factors influencing the 
susceptibility to or the severity of severe sepsis has been 
extensively studied. Several single nucleotide polymor-
phisms (SNPs) have been characterized in genes of NF-κB 
pathway proteins. For instance, SNPs in TLRs [22–24], 
TIRAP [25], IRAK1 [26, 27], IκB [28] and NF-κB inducing 
kinase (NIK) [29] genes have been associated with sever-
ity of sepsis. However, the association between genetic 
variants in NF-κB subunits and severe infections has been 
poorly reported. Hence, the present study aims to test the 
hypothesis of an association between clinically significant 
REL genetic variants and severity of septic shock in a large 
cohort of well-defined intensive care unit (ICU) patients.
Methods
Study population
This study was conducted prospectively in three medi-
cal ICUs in France. All three ICUs share similar severe 
sepsis management protocols based on international 
guidelines from the Surviving Sepsis Campaign for man-
agement of severe sepsis/septic shock [30]. The septic 
shock group was defined by usual criteria [31]. Briefly, 
patients were eligible for inclusion into the septic shock 
group (SS) if they had, within their stay in ICU, a clini-
cal evidence of infection with two of four SIRS criteria 
(fever (>38.2  °C) or hypothermia (<36  °C); tachycardia 
(>90  beats/min); tachypnea (>20  breaths/min) or need 
of mechanical ventilation; white cell count >12 × 109/L) 
and if, after an adequate fluid resuscitation, they required 
vasopressor infusion (norepinephrine, epinephrine 
or dopamine >8  μg/kg/min) to maintain a mean arte-
rial pressure higher than 60  mmHg. Exclusion criteria 
included comorbidities highly associated with death in 
SS [32]: age above 85 years, cardiac failure (NYHA class 
III or IV), liver insufficiency (child C), bone marrow apla-
sia or leucopenia not related to septic shock (white blood 
cell count <0.50 × 109/L), immunosuppression (HIV, cur-
rent immunosuppressive therapy including steroids with 
equivalent prednisone >0.5  mg/kg per day) or ongoing 
cancer with undergoing treatment.
The control group (C) was composed of patients hos-
pitalized simultaneously in the three ICUs for other rea-
sons than infection and who did not develop sepsis nor 
required any inotropic or vasopressor agents during their 
ICU stay. Similar exclusion criteria were used for the 
control and the SS groups.
Patients were followed up throughout their ICU stay, 
and clinical and biological characteristics were pro-
spectively collected: age, gender, SAPSII score and 
previous medical history of severe infection requiring 
hospitalization. For the SS group, characteristics of cur-
rent infectious episode were also collected: primary sites 
of infection, infection-related microorganisms, develop-
ment of multi-organ dysfunction syndrome (MODS) 
(defined as the presence of more than two organ system 
failures occurring simultaneously ICU stay) [3], mechani-
cal ventilation requirement estimated by ventilator-free 
day (VFD: time without mechanical ventilation within 
the ICU period censured to 28 days) [33] and ICU mor-
tality. To minimize confounding factors due to ethnical 
differences, all patients selected in the study were Cauca-
sians and had European origins.
Ethics approval
The Institutional Review Board of Cochin Hospital, Paris, 
France, approved the study, and informed consents have 
been obtained from the patients or their relatives.
Determination of genotypes, DNA isolation and allelic 
discrimination
Two previously described SNP have been analyzed. The 
SNP rs842647 is a A → G transition located in the sec-
ond intron of REL gene on chromosome 2 (chromosomic 
location 61119471). The SNP rs13031237 is a G  →  T 
transition located in the fourth intron of REL gene (chro-
mosomic location 61136129). All genetic analyses were 
performed blinded from the clinical data. Genomic DNA 
was extracted from mononuclear cells using MagNA 
Pure Compact automate (Roche Diagnostics®). DNA 
extracts were then quantified and stored in code-barr 
tubes (2DCYPHER, ABgene®) to maintain anonymous 
status of the patients all along the study. Real-time PCR 
allelic discrimination assays were realized by TaqMan® 
method on Abi 7900 (Applied Biosystems®). Probe and 
primer combinations were designed to discriminate the 
two REL SNPs (rs842647 and rs13031237). Quality con-
trol for genotyping was performed by automatic sequenc-
ing 12 patients carrying the different REL genotypes in 
order to confirm allelic discrimination results and also by 
re-genotyping 20  % of the entire cohort. All DNA sam-
ples showing discrepancy between the two analyses were 
definitively sequenced (n = 4).
Statistical analysis
All data were analyzed by SPSS v11.5 and “R” v3 soft-
wares. Both SNPs were tested for Hardy–Weinberg 
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disequilibrium to check for stratification. In order to 
calculate the Šidák multiple testing correction, we first 
evaluate the effective number of independent tests (called 
Meff) in the analysis by using the methodology proposed 
by Li and Ji [34]. This method aims to prevent from over-
correction due to possible linkage disequilibrium (LD) 
between the SNPs.
Power calculation has been based on the frequency of 
the variant allele in the control population as proposed 
by Hattersley et  al. [35]. Hence, for an incidence of the 
variant allele of 11  % in the control population and a 
power at 90  %, a 50  % increase in the case population 
with a type I error of 5 %, 886 individuals in each group 
appear to be sufficient to detect genetic susceptibility to 
SS (http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html). 
For the second study assessing the prognostic value of the 
variant alleles in SS group, given the frequency of the var-
iant genotype, and an expecting mortality rate at 35–40 % 
in the SS subgroup group, we considered that 870 SS 
patients were sufficient for a power at 0.90 (type I error at 
0.05) to identify a 30 % difference in genotype frequency.
Descriptive results of continuous variables were 
expressed as median and interquartile range reflecting 
population distribution. Variables were tested with Chi-
square test for categorical data (sex, multi-organ failure, 
primary sites of infection, microorganisms, genotypes) 
and with Mann–Whitney U test for numerical data (age, 
SAPSII, VFD).
A multivariate logistic regression model was used to 
determine the respective role of REL genotypes for sus-
ceptibility to SS and to ICU mortality. Confounding fac-
tors with a p value <0.05 were included in this model. 
Continuous variables were included without any trans-
formation, and genotypes were considered as a factor 
(dichotomous unordered variate) to avoid the implicit 
dose effect when coding the genotypes 0, 1 and 2 accord-
ing to the number of mutated alleles carried. Results were 
expressed as odds ratio (OR) and 95 % confidence inter-
val (CI), and variable with p value <0.05 was defined as 
statistically significant.
Results
Patient characteristics
The total enrolled Caucasian population was composed 
by 1040 septic shock patients (SS) and 855 controls 
(C). In the C group, enrolled ICU patients were admit-
ted for various non-infectious reasons (metabolic: 39 %, 
neurological: 29  %, respiratory: 22  %, cardiovascular: 
6 % and surgical: 4 %) and did not develop severe sepsis 
and did not require vasopressor infusion during their 
ICU stay. C patients were younger than SS patients (46 
vs. 66  years, respectively, p =  0.001), and females were 
more represented in C group (45 and 39 %, for C and SS, 
respectively, p = 0.006). Mortality rate and occurrence of 
MODS in the C group were 3 and 1 %, respectively.
All SS patients received norepinephrine or epinephrine 
as first vasopressor. The main site of infection was the 
lung (58  %); microorganisms were identified in 74  % of 
the cases, mainly Gram-positive bacteria. Median SAPSII 
value of 54 and high percentage of patients with multiple 
organ dysfunctions (61 %) underlined the severity of the 
septic shock population. The ICU mortality rate of the SS 
group was 30 %.
REL genotypes and septic shock susceptibility
Hardy–Weinberg proportions were comparable to 
expected percentages regarding REL variants: REL 
rs842647 (p = 0.9) and REL rs13031237 (p = 0.7) in favor 
of homogeneity of population ethnicity. To determine 
whether REL rs842647 and rs13031237 SNPs were asso-
ciated with septic shock susceptibility, genotype frequen-
cies were determined for SS and C patients. As reported 
in Table  1, no significant difference was found between 
the two groups. Moreover, these incidences were simi-
lar to those reported in the HapMap database-reported 
genotype distribution for European population (http://
www.ncbi.nhm.nih.gov/projects/SNP/snp_viewTable.
cgi?pop=1409).
REL genotypes and outcome of septic shock
Among the SS patients, general clinical characteristics 
were not significantly different between patients car-
rying REL minor allele and patients homozygous for 
major allele on both REL-analyzed loci (Table  2). In 
order to study the link between REL SNPs and septic 
shock severity, we compared acute respiratory distress 
syndrome (ARDS) and MODS frequencies, and VFD 
value between patients carrying REL rs842647*G and 
rs13031237*T minor alleles and in those homozygous for 
the major alleles. As given in Table  2, VFD values were 
Table 1 REL genotype frequencies
a Homozygous genotype
b p value control versus septic shock group for each genotype
Genotype (%) Minor  
allelea
Heterozygous Major  
allelea
p valueb
REL rs842647
 Control (n = 855) 8.9 42.2 48.9
 Septic shock (n = 1040) 9.7 42.9 47.4 0.74
REL rs13031237
 Control (n = 855) 13.5 44 42.6
 Septic shock (n = 1040) 11.4 46 42.6 0.38
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not different between these different groups of patients. 
The presence of rs13031237*T allele was not associated 
with higher risk of ARDS or MODS (Table 2). However, 
MODS occurred more frequently in patients carrying the 
REL rs842647*G allele [p = 0.04, OR 1.3, 95 % CI (1–1.7), 
Table 2]. For multiple testing correction, we calculated a 
Meff of 1.75 [34] leading to a corrected p value of 0.06. A 
similar trend was observed for ARDS (p = 0.08, Table 2).
REL genotypes and mortality of septic shock
In SS group, mortality was not significantly different 
between patients carrying REL rs13031237*T minor allele 
and homozygous for the major allele of this SNP (30.2 vs. 
29.8 %, for minor and major alleles, respectively, p = 0.9). 
In contrast, the presence of the rs842647*G minor allele 
was significantly associated with a higher mortality rate 
(33 vs. 27  %, for minor and major alleles, respectively, 
p = 0.03) (Fig. 1). Multivariate logistic regression analysis 
confirmed the importance of the rs842647*G minor allele 
for mortality risk during septic shock [OR 1.4, CI (1.02–
1.8), nominal p value = 0.03]. For multiple testing correc-
tion, the calculated Meff of 1.75 [34] led to a corrected p 
value of 0.05, which reaches near significance.
Discussion
The present study showed that septic shock patients car-
rying the rs842647*G minor allele had an over risk of 
MODS and mortality. In contrast, no association was 
found between the REL rs13031237*T allele and the 
severity of septic shock.
This study was the first to investigate the importance 
of two polymorphisms within REL gene in a large Euro-
pean population of septic shock patients. Several human 
studies have suggested that these variants may have an 
effect on the inflammatory balance, as they have been 
associated with inflammatory and autoimmune diseases. 
Indeed, the intronic rs13031237 SNP in the REL gene 
was associated with susceptibility to rheumatoid arthri-
tis [36–38] and psoriasis [39]. The intronic rs842647 SNP 
was linked to a higher risk of Crohn’s disease, ulcera-
tive colitis [40] and celiac disease [41, 42] and primary 
sclerosing cholangitis [43]. Genome-wide studies have 
also found that REL locus was associated with psoriasis 
[37, 44], rheumatoid arthritis [37], ulcerative colitis [45, 
46] and Hodgkin’s lymphoma [47]. However, functional 
and structural effects of these polymorphisms are still 
unknown and need to be investigated. Given that variant 
alleles are located on an intronic site, it is possible that 
these polymorphisms affect transcriptional efficiency of 
REL gene or these variants may be in strong linkage dis-
equilibrium with a variant inside a neighbor gene.
The higher rate of mortality observed in SS patients 
carrying rs842647*G might be linked to a higher inflam-
matory state, as they also developed more frequently 
MODS. They also tend to have more ARDS and lower 
VFDs however not significant, but this is most likely 
underpowered, as VFDs are not normally distributed. 
Mortality in septic shock was partially related to hyper-
activation of NF-κB [7, 48]. In this setting, previous 
genetic studies on several gain of function SNPs in genes 
of receptors and signaling molecules upstream of NF-κB, 
such as TLR1 and IRAK1 [22, 26], showed a significant 
association with severity of sepsis. These genetic factors 
might unbalance the fine-tune regulation toward a hyper-
inflammatory deleterious state. However, the exact role 
Table 2 Clinical characteristics of  SS group by REL geno-
type
a Homozygous for major allele
b Patients carrying minor allele and homozygous for major allele were 
compared: p value <0.05
c Continuous variables were expressed as median and interquartiles [25th 
percentile; 75th percentile]
Characteristics REL rs842647 REL rs13031237
G/G or A/G A/Aa T/T or A/T T/Ta
n = 493 n = 547 n = 443 n = 597
Agec 65 [52; 77] 67 [54; 77] 66 [53; 76] 65 [52; 77]
Men (%) 60.5 62.3 61.1 61.6
SAPSIIc 55 [43; 67] 53 [42; 67] 54 [43; 68] 54 [41; 66]
Diabetes (%) 22.1 17.3 19.9 19.7
COPD (%) 13.2 17.4 15.7 14.4
Septicemia (%) 27.7 29.9 29.5 27.7
Gram‑positive  
bacteria (%)
49.9 47.2 48.1 49.2
VFDc 8 [0; 20] 11 [0; 21] 10 [0; 20] 10 [0; 20]
ARDS (%) 38.6 33.5 34.8 37.9
Multiple organ  
dysfunctions (%)
63.9 57.8b 60.8 61.3
33%
27%
0%
20%
40%
G/G or A/G A/A
M
or
ta
lit
y 
(%
)
(n=493) (n=547)
∗
Fig. 1 rs842647*G allele is associated with increased mortality. G/G or 
A/G represented patients with septic shock who carried the variant 
rs842647*G allele. A/A represented patients with septic shock who 
were homozygous for the rs842647*A major allele. *p = 0.03
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of cRel on inflammatory processes is less understood in 
humans. Recent studies have shown that cRel could be 
involved in autoimmunity, such as inflammatory arthri-
tis [49] and autoimmune encephalomyelitis [50]. More 
recently, cRel was shown to have a key role in antimicro-
bial defense processes. Rel−/− mice are more susceptible 
to Leishmania major [9] or Toxoplasma gondii infections 
[10], to viral infection by Influenza virus [11], to bacterial 
infection by Listeria monocytogenes [12] and to polymi-
crobial sepsis [20]. cRel is probably important in pro-/
anti-inflammatory balance as Rel−/− mice seemed to 
have an enhanced inflammatory response [20].
The study design quality is important for a right inter-
pretation of genetic association studies [35]. We tried to 
follow closely these quality criteria. First, it is important 
to select a SNP of a protein involved in the physiopathol-
ogy of the disease. As already mentioned, REL seems to 
be an interesting gene to study because NF-κB plays a 
central role in physiopathology of sepsis, and recent stud-
ies show the importance of cRel in this context. How-
ever, one important limit of our study is the absence of 
data regarding the functional effect of these two SNPs. 
Functional data are needed to improve our understand-
ing of how rs842647*G variant of REL is related to sepsis 
severity. Second, the population homogeneity has been 
controlled by limiting the study on European patients 
without severe comorbidities. The third item is probably 
one of the more controversial in the sepsis field: choice 
of a clearly defined phenotype to avoid confusion factors. 
Thus, we have selected only patients with septic shock 
whose diagnosis and treatment are standardized [3], and 
these patients had no major comorbidity or immunosup-
pressive treatment, severe autoimmune diseases in par-
ticular, that could have been confounding the results. 
However, it is impossible to rule out effects of confound-
ing factors or gene–environment interactions in our 
results, and septic shock is heterogeneous with regard to 
the source of infection. Sample size is essential for statis-
tics quality in association study but is difficult to achieve 
in pure septic shock population. At our knowledge, our 
cohort is one of the largest ever published populations in 
this topic and is large enough to diminish type I error. It 
is important to consider that after correction for multiple 
testing, our result only reached near significance. Šidák/
Bonferroni correction assumes, however, that markers 
are independent, whereas the SNPs studied here are in 
LD and are therefore not truly independent from each 
other. As a result, though we tried to take into account 
LD by the calculation of Meff, the adjustment is likely 
to overcorrect in this case. We therefore consider that 
our preliminary results would need a validation in inde-
pendent cohorts. Finally, this genetic association study 
is limited to one gene. Genome-wide association studies 
(GWAS) are now discovering new unsuspected genes 
that might have an impact on sepsis outcome [51].
Conclusion
The association between rs842647*G allele and severity 
of septic shock brings a new perspective on the role of 
cRel subunit of NF-κB in severe infections in humans. 
Better understanding of the genetic effects of NF-κB-
dependent inflammatory pathways is essential for fur-
ther research on modulation of NF-κB activity by specific 
inhibitors, such as small molecule inhibitors  of cRel, as 
an adjuvant treatment for sepsis [52, 53]. Further studies 
are needed to investigate the functional role of this REL 
polymorphism on the inflammatory processes observed 
in sepsis and to validate these encouraging results in 
independent cohort.
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